CD44 and ovarian cancer: Their flow cytometry assay results pointed to a sixfold improved uptake of the multifunctional nanogel, in CD44- and EGFR-positive SKOV-3 ovarian cancer cells, compared to CD44-NG, as well as to increased cell apoptosis in vitro.